| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen |
| Not yet recruiting | 4 | 100 | Canada | Tezepelumab, Placebo | University of Alberta, AstraZeneca | Severe Asthma | 11/25 | 11/26 | | |
PASSAGE, NCT05329194: Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States |
|
|
| Active, not recruiting | 4 | 287 | US | Tezepelumab, AMG 157 or MEDI9929 | AstraZeneca, Parexel | Asthma | 10/25 | 10/25 | | |
2021-006691-17: A Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteriod Use in Adults with Oral Corticosteriod Dependent Asthma |
|
|
| Not yet recruiting | 3 | 207 | RoW | Tezepelumab via APFS, MEDI9929 anti-TSLP mAb (AMG157), Solution for injection in pre-filled syringe | AstraZeneca AB, AstraZeneca AB, Amgen | Severe Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Ongoing | 3 | 90 | Europe | Tezepelumab, Solution for injection in pre-filled syringe | University Hospital of Montpellier, AstraZeneca | exacerbating asthma, Severe asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05280418: Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma |
|
|
| Recruiting | 3 | 30 | Canada | Tezepelumab, Placebo | McMaster University | Asthma | 09/24 | 12/24 | | |
| Completed | 3 | 405 | RoW | Experimental: Tezepelumab, Tezepelumab, Placebo | AstraZeneca, Amgen | Asthma | 05/24 | 08/24 | | |
|
| Completed | 3 | 306 | Europe, US, RoW | Tezepelumab | AstraZeneca | Asthma | 09/24 | 09/24 | | |
| Completed | 3 | 416 | Europe, Canada, Japan, US, RoW | Experimental: Tezepelumab, Tezepelumab, Placebo | AstraZeneca, Amgen | Chronic Rhinosinusitis With Nasal Polyps | 09/24 | 12/24 | | |
|
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. |
|
|
| Recruiting | 3 | 300 | Europe, Canada, US, RoW | Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA | AstraZeneca, Fortrea | Severe Asthma | 06/27 | 06/27 | | |
ESSENCE, NCT06706817: A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab |
|
|
| Recruiting | 3 | 200 | Europe, Canada, US | Tezepelumab, TEZSPIRE® | AstraZeneca, Fortrea | Chronic Rhinosinusitis With Nasal Polyps | 01/27 | 01/27 | | |
NCT06740045: Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma |
|
|
| Not yet recruiting | 3 | 10 | NA | Tezepelumab, Teszpire | Dr. Andrew Thamboo, MD, AstraZeneca | Asthma, Chronic Rhinosinusitis With Nasal Polyps | 03/25 | 06/25 | | |
| Recruiting | 3 | 90 | Europe | Tezepelumab, placebo | University Hospital, Montpellier | Airway Remodelling, Asthmatic | 12/25 | 06/26 | | |
| Active, not recruiting | 3 | 124 | Europe, Canada, US, RoW | Tezepelumab, Placebo | AstraZeneca, Amgen | Asthma | 03/25 | 03/25 | | |
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Tezepelumab, Placebo | AstraZeneca, Amgen | Eosinophilic Esophagitis | 05/26 | 01/27 | | |
HORIZON, NCT06023589: A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma |
|
|
| Recruiting | 3 | 372 | Europe, Canada, Japan, US, RoW | Tezepelumab, MEDI9929 and AMG157, Placebo | AstraZeneca, Amgen | Asthma | 04/27 | 12/27 | | |
2022-000179-38: The effect of blocking TSLP signalling on airway inflammation in patients with chronic obstructive pulmonary disease |
|
|
| Not yet recruiting | 2 | 80 | Europe | tezepelumab, MEDI9929, Solution for injection in vial | Bispebjerg Hospital, AstraZeneca | Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease (COPD), Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Completed | 2 | 183 | Europe, Canada, Japan, US, RoW | Tezepelumab Dose 1, AMG 157, Tezepelumab Dose 2, Omalizumab, Xolair, Placebo | Amgen | Chronic Spontaneous Urticaria | 12/22 | 04/23 | | |
|
2022-003584-18: Tezepelumab (anti-TSLP-mab) in interstitial lung disease with progressive pulmonary fibrosis and elevated blood eosinophil granulocyte counts Tezepelumab (Anti-TSLP-mab) bei interstitieller Lungenerkrankung mit fortschreitender Lungenfibrose und einer erhöhten Anzahl von eosinophilen Granulozyten im Blut |
|
|
| Not yet recruiting | 2 | 39 | Europe | Tezspire, Solution for injection in vial, Tezspire | Philipps University Marburg, German Center of lung reserch, AstraZeneca | Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia, Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Completed | 2 | 337 | Europe, Canada, US, RoW | Tezepelumab, Placebo | AstraZeneca, Amgen | Chronic Obstructive Pulmonary Disease (COPD) | 11/23 | 01/24 | | |
|
| Recruiting | 2 | 19 | Canada | Tezepelumab, TEZSPIRE, tezepelumab-ekko | Dr. Anne Ellis | Asthma With Allergic Rhinitis | 04/26 | 04/26 | | |
RACEMATE, NCT06230354: Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis |
|
|
| Enrolling by invitation | 2 | 66 | Europe | Tezepelumab, Placebo | Imperial College London, AstraZeneca | EGPA - Eosinophilic Granulomatosis With Polyangiitis | 10/25 | 10/25 | | |
NCT05740748: Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma |
|
|
| Not yet recruiting | 2 | 34 | Canada | Tezepelumab, Placebo | McMaster University, University of Saskatchewan | Asthma, Allergic | 12/24 | 12/24 | | |
UPSTREAM-COPD, NCT05507242: Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD |
|
|
| Recruiting | 2 | 80 | Europe | Tezepelumab, Placebo | Asger Sverrild, AstraZeneca, University Hospitals, Leicester | COPD, COPD Exacerbation, COPD Bronchitis, Airway Disease, Immune System Disorder | 12/25 | 12/25 | | |
| Recruiting | N/A | 500 | RoW | Biological Treatment for severe asthma patients, Omalizumab, Mepolizumab, Benralizumab, Dupilzumab, Tezepelumab | Taichung Veterans General Hospital, E-DA Hospital, National Cheng-Kung University Hospital, National Yang Ming Chiao Tung University Hospital, Chang Gung Memorial Hospital | Pulmonary Disease, Asthma | 02/43 | 02/43 | | |
TPAP, NCT06455462: Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres |
|
|
| Recruiting | N/A | 200 | Europe | Tezepelumab | AstraZeneca | Severe Asthma | 04/25 | 04/25 | | |
NCT06438913: Tezepelumab Treatment in Korean Severe Asthma Patients |
|
|
| Not yet recruiting | N/A | 100 | NA | Tezepelumab | Asan Medical Center | Asthma | 05/25 | 12/26 | | |
T-ROSS, NCT06487065: Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain |
|
|
| Completed | N/A | 33 | Europe | | AstraZeneca | Severe Asthma | 10/24 | 10/24 | | |
ELBRUS, NCT06566885: Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia |
|
|
| Recruiting | N/A | 110 | RoW | | AstraZeneca | Severe Asthma | 06/25 | 06/25 | | |
TezEx, NCT06666504: The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The Study |
|
|
| Not yet recruiting | N/A | 150 | Europe | Combined Retrospective and Prospective Data Analysis | Guy's and St Thomas' NHS Foundation Trust, King's College London | Severe Asthma | 12/25 | 06/26 | | |
| Recruiting | N/A | 150 | Europe | | AstraZeneca | Asthma | 06/28 | 06/28 | | |
| Recruiting | N/A | 550 | Europe, Canada, RoW | None (Observational Study), Observational Study | AstraZeneca | Asthma | 03/26 | 03/26 | | |
| Active, not recruiting | N/A | 92 | Japan | | AstraZeneca | Asthma | 09/25 | 09/25 | | |
NCT05729711: TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS) |
|
|
| Recruiting | N/A | 400 | Japan | | AstraZeneca | Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy) | 11/29 | 11/29 | | |
